<DOC>
	<DOCNO>NCT00382889</DOCNO>
	<brief_summary>The aim study reveal inhale corticosteroid therapy combine short-acting beta2- agonist give symptom driven basis effective traditional asthma therapy . Thus , three advantage achieve : 1. good compliance treatment since patient likely administer treatment less frequently , 2. maximum pharmacological effect least amount drug 3. less economic burden health care provider .</brief_summary>
	<brief_title>As Needed Beclomethasone/Salbutamol Combination Single Inhaler Mild Persistent Asthma</brief_title>
	<detailed_description>Asthma widely recognise chronic inflammatory disorder airway . The 1997 American National Heart Lung Blood Institute ( NHLBI ) Guidelines state firm scientific basis exist indicate asthma result complex interaction among inflammatory cell , mediator cell tissue resident airway . Despite existence effective therapy people still die asthma . It pertinent state clinical effect drug dependent specific action drug , also patient ’ way use . Therefore , compliance important factor especially chronic disorder asthma . Indeed , non compliance asthma therapy serious problem . It report drug side effect , lifestyle , social economic factor , method drug delivery dose factor contribute poor compliance . The consequence poor compliance lead increase morbidity due increase symptom asthma exacerbation . The NHLBI Guidelines recommend daily treatment patient mild persistent asthma inhale glucocorticoid ( 200-500mcg/die ) short-acting bronchodilator need 3-4 time day . Comparisons : beclomethasone dipropionate 250 mg combine salbutamol 100 mg “ need ” , v salbutamol 100 mg alone “ need ” , vs beclomethasone 250 mg twice day plus salbutamol 100 mg “ need ” v beclomethasone dipropionate 250 mg combine salbutamol 100 mg twice day plus salbutamol 100 mg “ need ” , treatment patient mild persistent asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Clinical diagnosis mild persistent asthma define NHLBI/WHO 97 ; least 6 month ; FEV1 ³ 75 % predict normal value ; Positive response reversibility test b2 agonist , define increase &gt; 12 % FEV1 measure 30 minute follow 2 puff ( 2x100mg ) inhale Salbutamol spray , positive methacholine challenge ( PC20 &lt; 8mg/ml PD20 &lt; 1 mg ) within previous 6 month ; Stable asthma . Asthma define stable none follow occur last 14 day runin period : diurnal variation 20 % PEF 2 consecutive day ; use four inhalation b2 agonist per day two consecutive day ; need use oral corticosteroid ; COPD define ERS – Consensus Statement ; Patients 10 packs/year cigarette history current smoker ; History near fatal asthma and/or admission intensive care unit asthma ; One severe exacerbation runin period ; Three course oral corticosteroid hospitalisation asthma previous 1 year ; Patients treat 500 mcg/day beclomethasone equivalent 6 month previous last year ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Anti-Asthmatic Agents</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>symptom-driven</keyword>
	<keyword>beclomethasone</keyword>
	<keyword>salbutamol</keyword>
</DOC>